Cagrilintide
Research highlights
- ✓Long-acting amylin receptor agonist with weekly dosing profile
- ✓Complementary satiety mechanism to GLP-1 — different signalling pathway
- ✓Useful in combination studies with GLP-1 agonists
- ✓Emerging literature on cardiovascular and renal outcomes
Further reading: an independent guide to Cagrilintide ›
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue that acts on amylin receptors to reduce appetite and slow gastric emptying via a different pathway than GLP-1 agonists.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
Cagrilintide, explained
The short version: Cagrilintide is Novo Nordisk's long-acting copy of amylin, a fullness hormone made in the pancreas. It is best known as the partner in CagriSema, but it has its own trial record and now its own phase 3 programme.
What it is
Amylin is a hormone made in the pancreas that tells the brain you have had enough to eat. Cagrilintide is a long-acting version, given once a week in trials. Researchers describe it as a non-selective amylin receptor agonist, meaning it does not single out one receptor in the amylin family. That detail matters, because newer rivals such as eloralintide were designed to be more choosy.
What has been studied
The first big test was a phase 2 trial in The Lancet (2021): 706 adults on cagrilintide across 57 sites in ten countries, South Africa among them, compared with placebo and with daily liraglutide, an older GLP-1 drug. After 26 weeks, weight was down 10.8% at the highest dose tested, against 3.0% on placebo and 9.0% on liraglutide. Nausea, constipation, diarrhoea and injection-site reactions were the common complaints.
Cagrilintide also ran as its own arm inside the REDEFINE 1 phase 3 trial of CagriSema. Over 68 weeks that arm averaged 11.8% weight loss against 2.3% on placebo, first shown at the EASD meeting in 2025. Off the back of that, Novo started the RENEW phase 3 programme for cagrilintide alone in November 2025.
Where the evidence stops
On its own, cagrilintide sits at roughly half the weight loss of the combination, and RENEW has not reported yet. It is not approved anywhere as a single drug. All of the data come from Novo's pharmaceutical material in supervised trials, which tells you nothing about a research vial.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
A week-long amylin mimic with real human data, but on its own it trails the GLP-1 drugs by a clear margin.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Cagrilintide
No reviews from orders with Cagrilintide yet. Here is what recent customers said about ordering from us.
★★★★★
Great service as always
Nico V. · 6 Oct 2026
★★★★★
I am happy with my product
Kholofelo L. · 30 Sep 2026
★★★★
Small checkout glitch, but after following up it was quickly sorted out and everything went smoothly from there. Good customer service - thank you.
Tonia K. · 30 Sep 2026
★ 4.8 across all 16 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
+ GH-Axis entry — CJC-1295 + Ipamorelin
The same pairing in a single vial. Half the total peptide of the full stack below, and the cheaper way in.
+ Glutathione
The compound most often researched alongside a metabolic protocol.
+ AOD-9604
Filed in the same research area as the compound you are viewing.
+ GH-Axis — CJC-1295 + Ipamorelin
The GHRH + GHRP pairing most commonly researched alongside a GLP-1 protocol.
+ MOTS-c
A mitochondrial-derived peptide commonly researched alongside GLP-1 protocols.
+ Tesamorelin
A GHRH analogue often researched in GLP-1 body-composition work.
+ GHK-Cu
A copper peptide researched for skin & tissue alongside GLP-1 protocols.
+ NAD+
A cellular-energy & longevity-research staple paired with GLP-1 protocols.
